Cargando…
Phase II AIDS Malignancy Consortium (AMC) trial of imatinib in AIDS-associated Kaposi’s sarcoma (KS)
Autores principales: | Koon, Henry B, Honda, Kord, Lee, Jeannette Y, Christner, Susan M, Egorin, Merrill J, Noy, Ariela |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002723/ http://dx.doi.org/10.1186/1750-9378-5-S1-A61 |
Ejemplares similares
-
Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design
por: Krown, Susan E, et al.
Publicado: (2010) -
Pooled analysis of AIDS Malignancy Consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin’s lymphoma
por: Barta, Stefan K, et al.
Publicado: (2010) -
Four year survival in untreated AIDS related-Kaposi sarcoma (AIDS-KS) in Jos, Nigeria
por: Agaba, P, et al.
Publicado: (2009) -
Cancers associated with Kaposi's sarcoma (KS) in AIDS: a link between KS herpesvirus and immunoblastic lymphoma
por: Engels, E A, et al.
Publicado: (2001) -
Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study
por: Haigentz, Missak, et al.
Publicado: (2022)